Xu Da, You Guofeng
Department of Pharmaceutics, Rutgers University, 160 Frelinghuysen Road,Piscataway 08854, NJ, USA.
Department of Pharmaceutics, Rutgers University, 160 Frelinghuysen Road,Piscataway 08854, NJ, USA.
Adv Drug Deliv Rev. 2017 Jul 1;116:37-44. doi: 10.1016/j.addr.2016.05.003. Epub 2016 May 9.
Drug transporters encoded by solute carrier (SLC) family are distributed in multiple organs including kidney, liver, placenta, brain, and intestine, where they mediate the absorption, distribution, and excretion of a diverse array of environmental toxins and clinically important drugs. Alterations in the expression and function of these transporters play important roles in intra- and inter-individual variability of the therapeutic efficacy and the toxicity of many drugs. Consequently, the activity of these transporters must be highly regulated to carry out their normal functions. While it is clear that the regulation of these transporters tightly depends on genetic mechanisms, many studies have demonstrated that these transporters are the target of various post-translational modifications. This review article summarizes the recent advances in identifying the posttranslational modifications underlying the regulation of the drug transporters of SLC family. Such mechanisms are pivotal not only in physiological conditions, but also in diseases.
溶质载体(SLC)家族编码的药物转运蛋白分布于多个器官,包括肾脏、肝脏、胎盘、大脑和肠道,在这些器官中,它们介导多种环境毒素和临床重要药物的吸收、分布和排泄。这些转运蛋白表达和功能的改变在许多药物治疗效果和毒性的个体内和个体间差异中起重要作用。因此,必须高度调节这些转运蛋白的活性以使其发挥正常功能。虽然很明显这些转运蛋白的调节紧密依赖于遗传机制,但许多研究表明这些转运蛋白是各种翻译后修饰的靶点。这篇综述文章总结了在确定SLC家族药物转运蛋白调节的翻译后修饰方面的最新进展。这些机制不仅在生理条件下至关重要,在疾病中也很关键。